Amgen Inc AMGN:NASDAQ (Common Stock)

LastDaily Change / % ChangeDividend YieldVolumeAvg Volume (10 day)
180.53 -2.43   -1.33%2.51%2,571,2422.6M
Market data is delayed by at least 15 minutes.
Summary chart showing the current equity's performance of over the past 1 days
  • Advanced Charts
  • Embed the above chart in your blog or website

    Customize, copy, and then paste the generated code into your website.

Previous close 10/23/2017 (03:59 PM 10/23/2017 Eastern Standard Time)

Latest News Headlines for Amgen Inc

Amgen Announces Webcast of 2017 Third Quarter Financial Results

THOUSAND OAKS, Calif., Oct. 20, 2017 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that it will report its third quarter financial results on Wednesday, Oct. 25, 2017, after the close of the U.S. financial markets. The announcement will be followed by a conference call with the investment community at 2 p.m. PT. Participating in the call from Amgen will be Robert A. Bradway, chairman and chief executive officer, and other members of Amgen's senior management team.

Amgen And Boston Children's Hospital Enter A Collaboration To Find New Genes And Drug Targets For Severe Pain Syndromes

CAMBRIDGE, Mass., Oct. 16, 2017 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and Boston Children's Hospital today announced that they have entered into a neuroscience research collaboration aimed at identifying novel pain targets based on human genetic analyses. The one-year collaboration will focus on patients with genetic anomalies of pain sensitivity. Amgen will leverage its industry-leading expertise in genetic target identification and validation and will have access to Boston Children's Hospital's Division of Pain Medicine to identify patients with abnormal pain conditions. Amgen and Boston Children's Hospital will collaborate to validate the genetic findings as potential pain targets.

View more recent headlines

Peers Information HelpAMGN Amgen Inc vs. Peers

Amgen Inc
AbbVie Inc
Bristol-Myers Squibb Co
Eli Lilly and Co
Abbott Laboratories
Amgen Inc
AbbVie Inc
Bristol-Myers Squibb Co
Eli Lilly and Co
Abbott Laboratories
Amgen Inc
AbbVie Inc
Bristol-Myers Squibb Co
Eli Lilly and Co
Abbott Laboratories
Compare these stocks

Latest Annual and Quarterly SEC Filings

More Filings

This report contains detailed information about the company's business finances and management.


Quarterly reports contain financial statement, a discussion from management and a list of company events (stock splits, acquisitions, etc.)

Company Background

Amgen Inc. is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine). It focuses on human therapeutics for the treatment of serious illness in the areas of oncology/hematology, cardiovascular disease and neuroscience. Its product candidates in Phase III include Erenumab for episodic migraine, Aranesp for myelodysplastic syndromes, BLINCYTO for acute lymphoblastic leukemia and IMLYGIC for metastatic melanoma.


collapse, right-facing arrow indicating collapsed view of sectionOverview

A table providing an overview of the stock
Bid | Size-- | --
Ask | Size-- | --
Price Open183.25
Previous Close180.53
Day High183.62
Day Low180.37
52 Week High9/14/2017 | 191.0999
52 Week Low11/4/2016 | 133.64
% Off 52 Week High-5.53%
% Off 52 Week Low35.09%
Beta (5 Yr)1.4
Volatility Avg10/23/2017 | 21.81
10-Day Avg. Volume2,567,648
Market data is delayed by at least 15 minutes.

expand, down-facing arrow indicating expanded view of sectionFundamentals

A table providing the fundamentals of the stock
EPS (TTM)6/30/2017 | 11.00
P/E Ratio6/30/2017 | 16.4
Market CapLarge Cap | 131.73B
Shares Outstanding729.68M

collapse, right-facing arrow indicating collapsed view of sectionDividends

A table providing information about the dividends of the stock
Dividend Yield2.51%
Dividend Announcement7/28/2017
Date of Record8/17/2017
Payable$1.15 - QRTR
Payable Date9/8/2017

collapse, right-facing arrow indicating collapsed view of sectionShare Statistics

A table providing statistics about shares of the stock
Shares Short8.25M
Short Ratio3.4
Short % of Float1.13%
As of 9/29/2017
The performance data quoted represents past performance. Past performance does not guarantee future results. Current performance may be lower or higher than the performance quoted. Investment return and principal value of an investment will fluctuate and when redeemed, the investment may be worth more or less than their original cost.
The research, tools, and information provided will not include every security available to the public.